Sophie Valkenburg, principal investigator at HKU-Pasteur, and her colleagues from the Peter Doherty Institute for Infection and Immunity and the department of Infectious Diseases, St. Jude Children’s Research Hospital in Memphis publish a comprehensive review on the hope provided by the next-generation Influenza vaccines relying on T cells.
Sophie Valkenburg, HKU-Pasteur Research Pole
Using T cells to improve the limitations of current Influenza vaccines is definitely promising. However, before achieving a universal Influenza vaccine that harness the power of these immune cells, a myriad of questions remain to be addressed: which T cells are needed to fight the infection, and how, when and where to use this cells to unleash their therapeutic potential?
Find out more in the review published in Vaccines, a MDPI open-acces journal.
Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine E. Bridie Clemens, Carolien van de Sandt, Sook San Wong, Linda M. Wakim and Sophie A. Valkenburg Vaccines 2018, 6(2), 18; doi:10.3390/vaccines6020018